as 1402

Sontuzumab (AS1402) is a humanized monoclonal antibody targeting MUC1 that binds to the extracellular MUC1 peptide sequence PDTR (Kd≈1 nM) and can be used for breast cancer research.

JPI 547, also known as NOV 1402, is an oral inhibitor of PARP 1/2 and Tankyrase 1/2. JPI-547 demonstrated anti-tumor activity in BRCA-deficient xenograft models as a single-agent and in combination with chemotherapy and immune checkpoint inhibitors.

Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz serves as an ADC linker utilized in crafting ADCs (such as Trastuzumab deruxtecan and U3-1402). This compound facilitates the attachment of cytotoxic drugs to antibody molecules, enhancing targeted therapy effectiveness.